The Ansamycin Antibiotic, Rifamycin SV, Inhibits BCL6 Transcriptional Repression and Forms a Complex with the BCL6-BTB/POZ Domain

• Sian E. Evans,

  Affiliations Department of Biochemistry, University of Leicester, Leicester, United Kingdom, Department of Cancer Studies and Molecular Medicine and MRC Toxicology Unit, University of Leicester, Leicester, United Kingdom

  ⨯
• Benjamin T. Goult,

  Affiliation Department of Biochemistry, University of Leicester, Leicester, United Kingdom

  ⨯
• Louise Fairall,

  Affiliation Department of Biochemistry, University of Leicester, Leicester, United Kingdom

  ⨯
• Andrew G. Jamieson,

  Affiliation Department of Chemistry, University of Leicester, Leicester, United Kingdom

  ⨯
• Paul Ko Ferrigno,

  Current address: Avacta Life Sciences, Ltd, Thorp Arch Estate, Wetherby, United Kingdom

  Affiliation Section of Experimental Therapeutics, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom

  ⨯
• Robert Ford,

  Current address: Avacta Life Sciences, Ltd, Thorp Arch Estate, Wetherby, United Kingdom

  Affiliation Section of Experimental Therapeutics, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom

  ⨯
• John W. R. Schwabe,

  Affiliation Department of Biochemistry, University of Leicester, Leicester, United Kingdom

  ⨯
• Simon D. Wagner

  * E-mail: sw227@le.ac.uk

  Affiliation Department of Cancer Studies and Molecular Medicine and MRC Toxicology Unit, University of Leicester, Leicester, United Kingdom

  ⨯